The sea in the straits between China and Taiwan is at its calmest during these months, he informs me, making an invasion more likely. One of the many attractions of the remarkable island of Taiwan ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients.

A man with asthma, an Asian man at home sitting on the couch breathing in an inhaler People with type 2 diabetes are nearly twice as likely to develop asthma People with asthma also have an ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...

Taiwan plans to spend billions of dollars on seven more submarines in the next 14 years. Its first domestically built submarine was unveiled last fall and will undergo sea trials soon. Taiwan ...

China sent 50 military planes and vessels to the vicinity of Taiwan in the 24 hours starting at 6am on Friday, while President William Lai (賴清德) was visiting Kinmen for the first time since taking ...

The FDA has greenlighted Novartis’ Kisqali, used in combination with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer that’s at high ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.